Entera Bio Ltd
- Biotech or pharma, therapeutic R&D
Entera is a clinical stage company focused on developing oral peptide or protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care.
Our pipeline includes:
• Oral PTH(1-34) for Osteoporosis and other Metabolic Bone Disorders - Phase 3 ready
• Oral PTH for Hypoparathyroidism – Phase 1
• Oral GLP2 for Short Bowl Syndrome – IND enabling phase
• Oral GLP1 + Glucagon agonist (OXM) for Obesity – IND Filing Planned for H2 2025
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}